Aohua Pharmaceutical: The oral suspension of Fexofenadine Hydrochloride has obtained a drug registration certificate.

Kuihua Pharmaceutical announced that its subsidiary recently received a drug registration certificate issued by the National Medical Products Administration for the approval of the registration of oral suspension of Levocetirizine Hydrochloride. The drug specification is 120ml:0.72g and is classified as a Class 3 chemical drug, available by prescription only. This drug is suitable for relieving seasonal allergic rhinitis symptoms in children aged 2 and above and adults, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and above and adults.